Search Results

Some observers see risks to becoming over-reliant on local facilities, noting the potential need for trade partners if domestic production is disrupted.

Oligonucleotide Therapeutics Xchange – Europe 2025 will be held on 2nd December at the Hilton Munich Airport Hotel, bringing together senior pharma and biotech leaders to tackle challenges in therapeutic modalities, translational strategy, CMC/process development, and drug delivery. The program features expert-led roundtables, 1:1 meetings, presentations, and networking, creating an interactive environment to accelerate innovation in oligonucleotide therapeutics.

Antibody Therapeutics Xchange – Europe 2025 takes place on 1st December at the Hilton Munich Airport Hotel, bringing together senior pharma and biotech leaders. The agenda covers target selection, lead optimization, formats & scaffolds, bi/multispecifics, and AI/ML. With roundtables, 1:1 meetings, and networking, this interactive event is designed to drive collaboration and innovation in antibody therapeutics.

Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.